



## **Emmanuel Caeymaex**

**Executive Vice President Immunology Solutions & Head of US**

**Joined UCB in March 1994**

**Appointed in 2015**

**Date of birth: 1969**

**Nationality: Belgian**

### **Introduction & Professional experience**

Emmanuel leads the worldwide development and commercialization of innovative solutions that create unique value for people suffering from severe inflammatory and autoimmune disorders, such as psoriatic arthritis, axial spondyloarthritis, psoriasis, hidradenitis, lupus, rheumatoid arthritis, Crohn's disease as well as severe osteoporosis. He is also in charge of UCB's corporate activities in the US and leads the evolution of Medical Affairs and UCB's digital business transformation initiative.

Over the last 25 years Emmanuel has been instrumental in advancing UCB's transformation into a global biopharma company focused on patients with severe diseases. Prior to this appointment he led the Cimzia® Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCB's leadership position in epilepsy, successively as Global Brand Manager Keppra®, UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCB's operations in several Asia-Pacific markets for which he was awarded as Laureate of the Prince Albert Fund where he serves as President effective May 2019.

### **Education**

Emmanuel received a Business Engineer MSc degree from the University of Louvain (UCL), Belgium, a Master's in International Management from the Community of European Management Schools (CEMS) and continued his executive leadership development journey at INSEAD.

### **Main external appointments**

Member of the Board of BIO (Biotechnology Innovation Organization)

